Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellectis S.A. on October 8, 2021. The report serves as a disclosure of a material event concerning Allogene Therapeutics, Inc. ("Allogene"), a company in which Cellectis holds a significant interest. The filing details a clinical hold placed by the U.S. Food and Drug Administration (FDA) on Allogene's clinical trials.
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics for Cellectis S.A. or Allogene Therapeutics.
Material Changes and Clinical Update
The primary material event reported is the FDA's placement of a clinical hold on Allogene's trials following the detection of a chromosomal abnormality in a patient treated with ALLO-501A CAR T cells in the ALPHA2 study.
- Incident: A patient with Stage IV transformed follicular lymphoma developed pancytopenia. A bone marrow biopsy revealed aplastic anemia and ALLO-501A CAR T cells with a c-myc chromosomal rearrangement.
- Regulatory Action: The FDA has placed a hold on Allogene's clinical trials pending further investigation into the abnormality's clinical relevance and potential relationship to gene editing.
- Patient Status: The patient experienced Grade 1 cytokine release syndrome and Grade 2 neurotoxicity, achieved a partial response, and subsequently underwent an allogeneic stem cell transplantation to address prolonged cytopenia.
- Investigation: Allogene is conducting an investigation to characterize the abnormality, including evidence of clonal expansion, and expects to provide updates in the coming weeks after consulting with the FDA.
Outlook, Risks, and Management Commentary
Allogene reported that the FDA continues to actively review end-of-Phase 1 materials submitted in anticipation of a pivotal Phase 2 trial for ALLO-501A, though the current hold impacts this timeline. The filing notes that prolonged cytopenia requiring rescue stem cell transplantation has been previously reported in autologous CAR T therapies, suggesting this is a known risk category in the field, though the specific chromosomal abnormality requires further characterization.
Key Facts for Investor Verification
- Verify the current status of the FDA clinical hold on Allogene's trials and any subsequent communications from the FDA.
- Monitor Allogene's upcoming updates regarding the investigation into the c-myc rearrangement and its potential link to gene editing.
- Assess the impact of this clinical hold on Allogene's projected timeline for the pivotal Phase 2 trial of ALLO-501A.
- Review Cellectis S.A.'s financial exposure to Allogene Therapeutics to understand the potential financial impact of this regulatory event.